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Disease tolerance describes the ability of an infected host to limit disease severity without negatively impact-
ing the causative pathogen. Bessede et al. (2014) show that the aryl hydrocarbon receptor is an essential
component of disease tolerance during bacterial infection in mice.The pathologic outcome of infection is
revealed by the appearance of clinical
symptoms, reflecting a more or less pro-
nounced dysfunction of homeostasis
in the infected host. Depending on the
severity of disease, host reproductive
capacity and survival—fitness—might
eventually be compromised as well. It
follows that host defense strategies
against infection should share as a
common endeavor the preservation of
homeostasis and fitness. The prevailing
strategy to achieve this goal is to eliminate
the causative agent of disease, i.e., the
pathogen, via immune-driven resistance
mechanisms (Figure 1).
Host resistance mechanisms rely on
the recognition of pathogens by germ-
line-encoded pattern recognition recep-
tors (PRR), activating the host innate
immune system, which targets patho-
gens for destruction and/or expulsion
(Figure 1). Activation of adaptive immu-
nity provides a more specific, robust,
and long-lasting protection mechanism
against infection. Enhancing immune-
driven resistance mechanisms, e.g.,
through vaccination, has proven to be
an extremely efficient therapeutic strat-
egy against infectious diseases, relievingmankind from the evolutionary con-
straints imposed by many pathogens.
Presumably for this reason, we came
to consider immune-driven resistance
mechanisms as the only defense strategy
that really matters when taking into
consideration protection against infec-
tious diseases. Reality, however, is prob-
ably more complex.
The study by Bessede et al. (2014)
highlights the ‘‘relative cost’’ associated
with immune-driven resistance mecha-
nisms, as these become pathologic
and contribute to disease severity, i.e.,
immunopathology (Figure 1). Bessede
et al. (2014) show that this evolutionary
trade-off is reduced via an immunoregu-
latory mechanism involving a stress-
response pathway controlled by the aryl
hydrocarbon receptor (AhR) and con-
ferring disease tolerance to infection
(Figure 1).
Disease tolerance is a concept that
stems from observations made originally
in the context of infection in plants and
revealing that these can ‘‘tolerate’’ patho-
gens via a defense strategy that does not
appear to reduce their pathogen load but
instead limits the extent of tissue damage
associated with infection (Schaefer,1971). This defense strategy, coined as
tolerance, remained in the literature for
more than a century, as a specificity of
host-pathogen interactions in plants
(Schaefer, 1971). As it turns out, however,
tolerance is an evolutionary conserved
host defense strategy against infection
that is shared by plants and animals,
including insects, worms, mice, and
most likely humans as well (Medzhitov
et al., 2012). Disease tolerance is the
term used to describe the same concept
defined originally in the plant literature
and referring to preservation of host
fitness during infection, without con-
comitant reduction of pathogen load
(Medzhitov et al., 2012). The mechanisms
underlying disease tolerance in mammals
remain poorly understood, being linked so
far to stress-responsive pathways that
limit the extent of tissue damage caused
directly by pathogens or indirectly by
host immune-mediated resistance mech-
anisms (Figure 1; Figueiredo et al., 2013;
Jamieson et al., 2013; Larsen et al.,
2010). Bessede et al. (2014) propose
that the stress-response pathway regu-
lated by AhR is critically involved in
promoting disease tolerance to bacterial
infections in mice.
Figure 1. AhR and Disease Tolerance
Host soluble molecules and/or cells contributing to resistance mechanisms are labeled as the host
immune system. Other host cells and/or soluble molecules, which do not exert a negative impact on
pathogens, are labeled as the host parenchyma. Under homeostasis, fitness is governed to a large
extent by parenchyma. During infection, however, toxins and other virulence factors expressed by
pathogens can cause damage to the host parenchyma, driving homeostasis dysfunction and reducing
host fitness. Although immune-driven resistance mechanisms confer protection against infection by
reducing host pathogen load, they can also impose damage to the host parenchyma—immunopathology.
This is exacerbated by desequestration of endogenous PRR agonists, associated with tissue damage,
which promote sterile inflammation. Bessede et al. (2014) propose that L-kynurenine produced by
TDO2 in the host parenchyma (e.g., liver) or by IDO1 within the immune system (e.g., macrophages
and dendritic cells) is sensed by AhR, which regulates a stress-response exerting immunoregulatory
effects that promote immune-driven resistance as well as disease tolerance. The immunoregulatory effect
driven by TDO2 and AhR involves IL-10 while that driven by IDO1 and AhR involves TGF-b. Note that
induction of AhR activity by L-kynurenine produced by TDO1 phosphorylates IDO1 (pIDO1) via the Scr
kinase to produce more L-kynurenine and hence activate AhR further, forming a possible positive forward
feedback loop.
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ligand-activated transcription factor, well
known to toxicologists for its ability
to sense xenobiotics—foreign molecules
potentially toxic to the organism (Denison
and Nagy, 2003). The dual action of AhR
as a sensor and transcriptional regulator
allows for a versatile stress response
that provides cellular and systemic adap-
tation to xenobiotics (Hankinson, 1995).
Over the years it has become apparent
that AhR also senses endogenous ligands
but the identification and physiologic
relevance of these molecules has re-
mained elusive. Moreover, several studies
have highlighted that AhR exerts immu-
noregulatory effects that restrain the
pathogenesis of immune-mediated in-
flammatory conditions, including infec-
tious diseases (Stockinger et al., 2014).
The findings now reported by Bessede
et al. (2014) are in keeping with previous
studies, revealing that L-kynurenine is
a physiologic AhR agonist, required to
support the protective effect of AhR
against infectious diseases.
L-kynurenine is an endogenous prod-
uct of tryptophan catabolism, generatedphysiologically in mammals by the tryp-
tophan 2,3-dioxygenase (TDO or TDO2)
as well as by indoleamine 2,3-dioxyge-
nases (IDO) 1 and 2, the latter being
well known for their immunoregulatory
effects (Mellor and Munn, 2004). Using
a genetic loss-of-function approach in
mice, Bessede et al. (2014) demonstrate
that when expressed under physiologic
conditions, AhR and TDO2 are both
required to confer host protection against
endotoxic shock. This salutary effect is
dependent on L-kynurenine, generated
via TDO2 activity, with exogenous L-ky-
nurenine administration bypassing the
requirement for TDO2 but not for AhR
expression and/or activity. The notion
that tryptophan catabolism supports
functionally the protective effect of
AhR is further strengthened by the
demonstration that L-kynurenine is
indeed an AhR ligand. Considering that
disruption of homeostasis associated
with endotoxic shock is driven by the
engagement of the PRR toll-like recep-
tor 4 (TLR4) by the bacterial ligand
lypopolysaccharide (LPS), in the absence
of living bacteria, the protective effectImmunity 41of AhR and TDO2 is likely to partici-
pate in a disease tolerance pathway, as
claimed.
Bessede et al. (2014) assessed
whether this disease tolerance pathway
is involved in LPS (endotoxin) tolerance,
a phenomenon familiar to immunolo-
gists, in which a low level of TLR4
engagement confers protection against
subsequent exposure to a lethal dose
of LPS causing endotoxic shock. They
found that AhR and IDO1 are both
required for LPS tolerance in mice.
Exogenous L-kynurenine administration
bypasses the need for IDO1 but not
for AhR expression and/or activity, sug-
gesting that in this context AhR senses
L-kynurenine produced mainly by IDO1.
Presumably during the course of an
infection, AhR senses L-kynurenine pro-
duced initially by TDO2, which activates
AhR. This promotes the phosphorylation
of IDO1, through a mechanism involving
the Src kinase, and leading to the pro-
duction of L-kynurenine, sustaining AhR
activation. This argues for the establish-
ment of a positive feed forward loop in
which AhR activation induces the gener-
ation of L-kynurenine, via IDO1 activity,
engaging further AhR to promote LPS
tolerance.
Bessede et al. (2014) used a similar
experimental approach to establish that
LPS tolerance confers protection against
bacterial infections, possibly via the AhR
and L-kynurenine pathway. This is shown
to be the case for Salmonella Typhimu-
rium and Streptococcus infection in
mice, inferring that LPS tolerance con-
fers disease tolerance to bacterial infec-
tions. However, this protective effect is
associated with a significant decrease
in host pathogen load in both experi-
mental models of infection tested. This
argues that although critical to preserve
host homeostasis and fitness during bac-
terial infection, LPS tolerance enhances
not only disease tolerance but also resis-
tance to infection, presumably acting via
AhR and L-kynurenine. The latter was
not demonstrated unequivocally for live
bacteria.
This study by Bessede et al. (2014) also
raises several questions possibly leading
to future lines of research. AhR-deficient
mice appear to be far more susceptible
to endotoxic shock, as compared to
TDO2-, IDO1-, or IDO2-deficient mice.
This would argue that the protective effect, August 21, 2014 ª2014 Elsevier Inc. 177
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lent than the one exerted by enzymes
generating its physiologic ligands, e.g.,
L-kynurenine. There are at least two
possible and non-mutually exclusive ex-
planations for this. The first is that the
enzymes involved in tryptophan catabo-
lism are to some extent redundant in
their ability to produce the AhR ligand
L-kynurenine. Alternatively, it is possible
that additional AhR ligand(s) are produced
physiologically via other host catabolic
pathways that support the protective
effects of AhR. Candidate AhR ligands
include those produced by heme oxy-
genases (HOs), a stress-responsive
enzyme that confers disease tolerance
to polymicrobial infection (Larsen et al.,
2010). Heme catabolism by HOs pro-
duces several putative AhR ligands
including biliverdin (a direct end-product
of HO activity) and bilirubin (a potent anti-
oxidant generated from biliverdin catabo-
lism by biliverdin reductase that activates
AhR) (Denison and Nagy, 2003). More-
over, heme catabolism by HOs also
generates carbon monoxide, a gaso-
transmitter that can bind ferrous (Fe2+)
iron contained in the heme group of AhR178 Immunity 41, August 21, 2014 ª2014 Elsand modulate its activity. Whether regula-
tion of disease tolerance by AhR acts via a
mechanism involving the putative action
of different end products of heme catabo-
lism by HOs has not been established. If
proven correct, this would argue for the
integration of the AhR signal transduction
pathways in a wider network of stress-
responsive signaling pathways regulating
disease tolerance to infection.
Although simple in its essence, the
concept of disease tolerance should
have major implications to our current
understanding of the pathogenesis of in-
fectious diseases. The study by Bessede
et al. (2014) and future studies should pro-
vide the mechanistic insight, i.e., ‘‘nuts
and bolts,’’ allowing for targeting this de-
fense strategy therapeutically toward a
much-needed supplement to the current
clinical approaches available in the treat-
ment of infectious diseases.
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Lymphocytes normally develop within anatomically distinct tissues. In Cell Reports, Swann et al. (2014)
reconstruct the primordial thymus and suggest that it was a site of combined T and B lymphopoiesis before
evolving into an organ specialized for T cell production.Through random recombination of gene
segments encoding antigen receptors,
lymphocytes recognize a wide range of
pathogens and represent key players in
adaptive immunity. They are also hetero-
geneous: B cells produce antibodies
recognizing antigen in its native form,
while ab T cells recognize antigenic
peptides via major histocompatibilitycomplexes (MHC). In vertebrates, this
lymphocyte heterogeneity is mirrored in
the tissues that support their generation.
Thus, bursectomy and thymectomy ex-
periments in birds showed antibody-pro-
ducing cells, and cytotoxic lymphocytes
arose in anatomically distinct sites
(Cooper et al., 1966). Significantly, studies
on jawless vertebrates show that thespecialized T lymphopoietic role of the
thymus is ancient. For example, epithelial
regions of developing lamprey gill struc-
tures express Foxn1 (Bajoghli et al.,
2011) encoding a transcription factor
essential for thymic epithelial cell (TEC)
development. Moreover, these tissues
contained lymphocytes with features of
T cells (e.g., expression of variable
